Skip to content
value.today

GenVec

GNVCUnlisted company
No market cap data
Compare
World rank
—
no current market cap
Revenue
$1 M
For year ending December-2016
Net income
$-6 M
-1135.3% margin
SEC filing
Employees
15
As of February 28, 2017
SEC filing

GenVec in brief

GenVec is an unlisted company in the Biotechnology industry, based in Gaithersburg, USA. In the year to December 2016 it had sales of $1 M and a net loss of $6 M. It employs about 15 people.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About GenVec

GenVec, Inc. is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its proprietary AdenoVerse™ gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. We are pioneers in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. Our lead product candidate, CGF166, is licensed to Novartis Institutes for BioMedical Research, Inc. and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, we also focus on opportunities to license our proprietary technology platform, including vectors and production cell lines, to potential collaborators in the biopharmaceutical industry for the development and manufacture of therapeutics and vaccines.

From the company's annual report filed with the US SEC: read the report

GenVec timeline

1 events, 1998
  1. 1998
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of GenVec from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about GenVec

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 16 June 2017 (Form 8-K).

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-1135.3%
Operating margin
-1415.7%
Return on equity
-123.2%
Liabilities / assets
38.9%
Revenue growth
-42.0%
R&D / revenue
490.2%
Revenue per employee
$34 K
Profit per employee
$-386 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2009: revenue $14M, net income $-18M$14MFY09Fiscal year ending Dec 2010: revenue $16M, net income $-12M$16MFY10Fiscal year ending Dec 2011: revenue $18M, net income $-7M$18MFY11Fiscal year ending Dec 2012: revenue $9M, net income $-14M$9MFY12Fiscal year ending Dec 2013: revenue $4M, net income $-10M$4MFY13Fiscal year ending Dec 2014: revenue $6M, net income $-3M$6MFY14Fiscal year ending Dec 2015: revenue $1M, net income $-7M$1MFY15Fiscal year ending Dec 2016: revenue $1M, net income $-6M$1MFY16
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2016$1M-42.0%$-7M$-6M-1135.3%
Dec 2015$1M-85.4%$-7M$-7M-743.2%
Dec 2014$6M+64.1%$-3M$-3M-41.7%
Dec 2013$4M-60.6%$-10M$-10M-272.3%
Dec 2012$9M-47.3%$-14M$-14M-150.4%
Dec 2011$18M+7.7%$-7M$-7M-41.9%
Dec 2010$16M+18.8%$-13M$-12M-74.5%
Dec 2009$14M—$-18M$-18M-132.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2016$-6M$0M$-6M$-2.78—
Dec 2015$-6M$0M$-6M$-3.90—
Dec 2014$-2M$0M$-2M$-0.16—
Dec 2013$-9M$0M$-10M$-0.77—
Dec 2012$-11M$0M$-11M$-1.09—
Dec 2011$-8M$0M$-9M$-0.58—
Dec 2010$-11M$0M$-11M$-0.97—
Dec 2009$-17M$0M$-17M$-1.89—

SEC filings

Official filings of GenVec with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-7 M
Net income
$-6 M

For year ending December-2016 · source: SEC filing

Balance sheet

Total assets
$8 M
Total liabilities
$3 M
Total equity
$5 M

As of December-2016

Insider trading at GenVec#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
17
since
GenVec: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Marc R. SchneebaumDirectorOption exercise+1,500$3.800$6 K9,050Form 4
filed Douglas E. BroughChief Scientific OfficerOption exercise+13,000$5.600$73 K26,668Form 4
filed Douglas J. SwirskyPresident and CEO, DirectorOption exercise+25,000$5.600$140 K50,250Form 4
filed James Vincent LambertVP, Accounting & FinanceOption exercise+4,000$5.600$22 K5,981Form 4
filed Bryan T. ButmanSenior Vice PresidentOption exercise+6,000$5.600$34 K14,138Form 4
filed Willam N. KelleyDirectorOption exercise+1,500$3.800$6 K9,050Form 4
filed Quinterol J. MalletteDirectorOption exercise+1,500$3.800$6 K1,500Form 4
filed Stefan LorenDirectorOption exercise+1,500$3.800$6 K2,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

GenVec scorecard#

Passes 2 of the 8 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (0 of 3). Fiscal year 2016.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 3
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.78 vs -3.90Diluted EPS -2.78 in fiscal 2016 against -3.90 the year before (report's currency).
    • ✓Net income higher than five years earlier-$6 M-$6 M in fiscal 2016 against -$7 M in 2011.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2016.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2016.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2016.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-93.5%-93.5% in fiscal 2016.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities4.0×Current ratio 4.03 at the end of fiscal 2016.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2016.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

GenVec: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

GenVec: statements by fiscal year
PeriodTrendFY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014FY 2013to Dec 31, 2013FY 2012to Dec 31, 2012FY 2011to Dec 31, 2011FY 2010to Dec 31, 2010FY 2009to Dec 31, 2009
Income statement
Revenue0.50.96.03.79.4181614
Research and development2.52.62.35.514172125
General and administrative5.24.96.38.59.17.88.27.2
Operating expenses7.77.58.61423252932
Operating income−7.2−6.6−2.5−10−14−7.5−13−18
Other non-operating income (expense)1.40.0——0.00.00.3−0.4
Net income attributable to shareholders−5.8−6.5−2.5−10−14−7.4−12−18
Earnings per share, basic-2.78-3.90r-0.16-0.77-1.09-0.58-0.97-1.89
Earnings per share, diluted-2.78-3.90r-0.16-0.77-1.09-0.58-0.97-1.89
Shares, weighted average (diluted)0.00.0r0.0r13————
Balance sheet
Cash and cash equivalents3.77.08.05.24.24.13511
Short-term investments————11220.2—
Receivables0.00.20.30.20.92.7r3.2—
Other current assets0.30.20.20.30.20.20.2—
Current assets7.59.1156.61629r39—
Property, plant and equipment0.20.30.30.50.80.70.7—
Total assets7.79.5167.31730r39—
Accounts payable1.01.11.11.01.51.5r1.1—
Current liabilities1.81.72.22.63.73.6r6.9—
Total liabilities3.01.82.32.63.73.6r7.0—
Retained earnings−291−285−278−276−266−252−244—
Shareholders' equity4.77.7134.61427327.6
Total liabilities and equity7.79.5167.31730r39—
Shares outstanding2.3r0.0r17r14r1313r13—
Cash-flow statement
Depreciation and amortization0.10.10.20.20.20.20.21.1
Share-based compensation0.80.90.50.91.31.61.91.7
Cash from operating activities−6.0−5.9−2.0−9.3−11−8.5r−11−17
Capital expenditure−0.0−0.1−0.0−0.4−0.4−0.2−0.3−0.2
Cash from investing activities−1.95.0−5.91011−22r−0.32.8
Debt repaid———————−0.5
Shares issued4.5−0.011—————
Cash from financing activities4.5−0.011000.03511
Change in cash−3.3−1.02.71.10.0−3124−3.4
Report10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2017. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at GenVec#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Delisting notice 3 · Auditor changed 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 2 · Unregistered share sale 1 · Shareholder rights changed 2 · Bylaws or fiscal year changed 3 · Shareholder vote 4 · Results announced 9

GenVec: events reported to the SEC
FiledWhat happenedFiling
Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersShareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Delisting notice8-K
Material agreementShareholder rights changed8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Shareholder vote8-K
Delisting notice8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jun 16, 2017

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of GenVec
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2010$2 MNo. 1$2 to $10 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at GenVec#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
86
2006–2013
Latest
41 people
2013-06-25
GenVec: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2013·····41······41
2012········23···23
200922···········22
2006············—
GenVec: latest layoffs
AnnouncedPeopleKindWhereSource
41 peopleRestructuring planSEC 8-K“(the “Company”) announced that it is terminating the employment of 30 of its remaining 41 employees.”Filing
23 people (30% of workforce)Restructuring planSEC 8-K“(the “Company”) announced that it is lowering its operating costs to conserve capital, including eliminating 23 positions, or approximately 30% of its workforce.”Filing
22 peopleRestructuring planSEC 8-K“On January 29, 2009, GenVec, Inc. announced that it is lowering its operating costs in order to increase the Company’s efficiency, including eliminating 22 positions.”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How GenVec compares in Biotechnology

  • Revenue$1 M · higher than 21% of 647
  • Revenue growth-42.0% · higher than 22% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
GenVec🇺🇸———-42.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2016
Balance sheet:
As of December-2016
Employees:
As of February 28, 2017
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, SEC annual report, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at GenVec? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show GenVec's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about GenVec? Suggest a correction